



Suppl. Figure S4: Systemic S12 does not alter proliferation, apoptosis and angiogenesis of Kelly NB tumors. 2×10^6 Kelly cells were injected s.c. into the left flank of athymic mice. After 7 days mice received i.p. injections three times per week with 30 mg/kg of S12 while control group received PBS with 40% PEG. Tumors of 4-5 mice per group were formalin-fixed, paraffin-embedded, stained and analyzed. **A) Proliferation of Kelly cells is not affected by S12 treatment.** Representative Ki67 stains are shown in the left panel, respectively. Ki67-positive cells were counted as % of nucleated cells in 5-9 representative visual fields (x40) and are depicted as means and standard deviations (right panel). **B) S12 treatment does not induce apoptosis in Kelly tumors.** Representative active caspase 3 stains are shown in the left panel, respectively. Active caspase 3-positive cells were counted as % of nucleated cells in 5-7 representative visual fields (x40) and are depicted as means and standard deviations (right panel). **C) Systemic injection of S12 does not alter tumor vessel formation.** Representative CD31 stains are shown in the left panel, respectively. CD31-positive vessels were counted in 4-8 representative visual fields (x20) and are depicted as means and standard deviations (right panel). Statistical analysis was performed using the unpaired two-tailed t-test. n.s., not significant. Scale bars equal 100 μ m.